Joseph Douglas  Lyon net worth and biography

Joseph Lyon Biography and Net Worth

Currently, J. D. Lyon is Chief Accounting Officer of Corcept Therapeutics, Inc.

In the past he occupied the position of Director-Operations Business Development at Connor Group, Worldwide Corporate Controller & General Manager at Zinfi Technologies, Inc. and Auditor at Ernst & Young, Inc.

He received an undergraduate degree from the University of Utah.

What is Joseph Douglas Lyon's net worth?

The estimated net worth of Joseph Douglas Lyon is at least $171,517.68 as of February 16th, 2024. Mr. Lyon owns 6,774 shares of Corcept Therapeutics stock worth more than $171,518 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Lyon may own. Learn More about Joseph Douglas Lyon's net worth.

How old is Joseph Douglas Lyon?

Mr. Lyon is currently 45 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on Joseph Douglas Lyon's age.

How do I contact Joseph Douglas Lyon?

The corporate mailing address for Mr. Lyon and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Joseph Douglas Lyon's contact information.

Has Joseph Douglas Lyon been buying or selling shares of Corcept Therapeutics?

Within the last three months, Joseph Douglas Lyon has sold $26,000.00 in shares of Corcept Therapeutics stock. Most recently, Joseph Douglas Lyon sold 1,000 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $26.00, for a transaction totalling $26,000.00. Following the completion of the sale, the chief accounting officer now directly owns 6,774 shares of the company's stock, valued at $176,124. Learn More on Joseph Douglas Lyon's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 266,012 shares worth more than $7,383,113.80. The most recent insider tranaction occured on March, 18th when insider Sean Maduck sold 17,219 shares worth more than $430,475.00. Insiders at Corcept Therapeutics own 18.6% of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 3/18/2024.

Joseph Douglas Lyon Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2024Sell1,000$26.00$26,000.006,774View SEC Filing Icon  
12/4/2023Sell2,432$26.00$63,232.005,854View SEC Filing Icon  
12/1/2023Sell2,568$26.00$66,768.005,854View SEC Filing Icon  
11/2/2023Sell3,977$28.11$111,793.475,854View SEC Filing Icon  
10/6/2023Sell2,582$27.24$70,333.685,854View SEC Filing Icon  
10/2/2023Sell2,418$27.25$65,890.505,854View SEC Filing Icon  
9/1/2023Sell5,000$32.73$163,650.005,132View SEC Filing Icon  
8/21/2023Sell4,588$31.19$143,099.725,132View SEC Filing Icon  
8/7/2023Sell412$31.22$12,862.644,720View SEC Filing Icon  
6/6/2023Sell10,000$23.60$236,000.005,132View SEC Filing Icon  
4/1/2021Sell25,000$23.88$597,000.0025,000View SEC Filing Icon  
2/3/2021Sell25,000$29.18$729,500.0025,000View SEC Filing Icon  
1/4/2021Sell25,000$26.13$653,250.004,167View SEC Filing Icon  
See Full Table

Joseph Douglas Lyon Buying and Selling Activity at Corcept Therapeutics

This chart shows Joseph Douglas Lyon's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $25.32
Low: $24.59
High: $25.36

50 Day Range

MA: $23.33
Low: $21.10
High: $25.32

2 Week Range

Now: $25.32
Low: $20.87
High: $34.28

Volume

746,706 shs

Average Volume

1,619,045 shs

Market Capitalization

$2.62 billion

P/E Ratio

26.65

Dividend Yield

N/A

Beta

0.47